Bacteriocins are ribosomally synthesised antimicrobial peptides produced by bacteria, and nisin is the best characterised and most widely used example.
Key Takeaways
- Unlike many antimicrobial peptides, bacteriocins are gene-encoded products of bacterial competition rather than host defence molecules.
- Nisin contains lanthionine and methyllanthionine bridges formed by post-translational modification.
- Other bacteriocins are being explored for clinical and veterinary use, particularly against resistant organisms.
What distinguishes bacteriocins
Unlike many antimicrobial peptides, bacteriocins are gene-encoded products of bacterial competition rather than host defence molecules. This matters practically because they are produced by fermentation and can be manufactured at scale.
Nisin’s mechanism
Nisin binds lipid II, a cell-wall precursor, and uses it to form pores in the target membrane. The dual mechanism of blocking cell-wall synthesis and forming pores explains its potency and the difficulty of resistance development.
For related mechanism work, see peptide metal chelation.
Lanthionine ring structure
Nisin contains lanthionine and methyllanthionine bridges formed by post-translational modification. These rings constrain the structure and are essential to activity, which is why the molecule is classified as a lantibiotic.
Food preservation use
Nisin is used as a food preservative with a long safety record, and it is one of the few antimicrobial peptides with genuine commercial application. Its success is a useful counterweight to the therapeutic disappointments in the wider class.
Broader interest
Other bacteriocins are being explored for clinical and veterinary use, particularly against resistant organisms. The same selectivity and stability constraints that limit other antimicrobial peptides apply here.
Experimental Conditions and Practical Setup
Activity is measured against a susceptible indicator strain in a standardised medium, with the peptide quantified rather than added by mass of a preparation of unknown potency. Because nisin is produced by fermentation, activity is expressed in international units relative to a standard rather than in weight, and this is stated in any comparison.
Nisin properties relevant to application
| Property | Detail | Practical consequence |
|---|---|---|
| Mechanism | Lipid II binding plus pore formation | Dual action limits resistance |
| Structure | Lanthionine ring lantibiotic | Rings essential for activity |
| Production | Fermentation | Scalable manufacture |
| Application | Food preservation | Long safety record in food use |
Practical Notes for the Bench
- Note the dual lipid-II binding and pore-forming mechanism of nisin.
- Recognise lanthionine rings as essential structural features.
- Separate food-preservation success from therapeutic application.
Frequently Asked Questions
What makes nisin effective?
It binds lipid II to block cell-wall synthesis and simultaneously forms membrane pores, a dual mechanism that also limits resistance.
Is nisin used commercially?
Yes, as a food preservative with a long safety record, which is unusual among antimicrobial peptides.
What is a lantibiotic?
An antimicrobial peptide containing lanthionine bridges formed by post-translational modification, a feature essential to its activity.
Is resistance to nisin impossible?
No. The dual mechanism makes resistance structurally harder to acquire than for a single-enzyme target, but it should not be assumed impossible.
Related Reading
- peptide metal chelation
- food-derived bioactive peptides
- glutathione peptide research
- AOD-9604 peptide
- reproducible peptide experiments
References & Further Reading
- Field D et al. After a century of nisin research – where are we now?. FEMS Microbiol Rev. 2023. PubMed 37300874
- Delves-Broughton J et al. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek. 1996. PubMed 8775979
- Zhao C et al. Nisin a probiotic bacteriocin mitigates brain microbiome dysbiosis and Alzheimer’s disease-like neuroinflammation triggered by periodontal disease. J Neuroinflammation. 2023. PubMed 37803465
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Dr. Elena Marchetti, Peptide Chemistry & Analytical Characterization.